Tokyo, Japan

Kousuke Nakagawa

This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Nemoto Kyorindo Co., Ltd.. Active years: 2021.


% Patents Active = 100.0

 

Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2021

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Kousuke Nakagawa: Innovator in Injecting Apparatus Technology

Introduction

Kousuke Nakagawa is a notable inventor based in Tokyo, Japan. He has made significant contributions to the field of medical technology, particularly in the design of injecting apparatuses. His innovative approach aims to enhance the reliability and safety of chemical liquid injections.

Latest Patents

Kousuke Nakagawa holds a patent for an injecting apparatus and rear end detection device. This invention features a pushing unit that stops just before making contact with the rear end of a syringe. This design effectively prevents unwanted extrusion of a chemical liquid from the syringe. The apparatus includes an injection head for mounting the syringe, a pushing unit that engages the rear end of the syringe, a contactless rear end detection unit, and a control unit that manages the operation of the injection head.

Career Highlights

Kousuke Nakagawa is associated with Nemoto Kyorindo Co., Ltd., where he has been instrumental in developing advanced medical devices. His work focuses on improving the precision and safety of injection systems, which are critical in various medical applications.

Collaborations

Kousuke has collaborated with notable colleagues such as Shigeru Nemoto and Hirofumi Uchizono. Their combined expertise has contributed to the successful development of innovative medical technologies.

Conclusion

Kousuke Nakagawa's contributions to the field of injecting apparatus technology demonstrate his commitment to enhancing medical safety and efficacy. His innovative designs continue to influence the industry positively.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…